ArticleiScience2025
Protein arginine methylation regulates anti-inflammatory programming in response to aging stress.
Article in iScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PRMT1 is a key enzyme responsible for protein arginine methylation, which regulates various cellular processes. However, its physiological significance at whole-body level remains unknown due to embryonic lethality of Prmt1-null mice. Despite only one amino acid difference at position 179, molecular dynamics simulations and biochemical assays showed that human PRMT1 exhibits enhanced methyltransferase activity compared to its mouse counterpart. Capitalizing on this finding, we generated humanized PRMT1 knock-in mice (huMice) carrying the H179Y substitution. Notably, huMice displayed distinct transcriptomic signatures associated with attenuated inflammatory responses compared to wild-type mice in an age-dependent manner. In particular, huMice exhibited reduced pro-inflammatory cytokines production following lipopolysaccharide (LPS) challenge at 12 months, revealing that heightened PRMT1 activity confers a physiological advantage in alleviating age-related inflammatory stress. Our findings underscore PRMT1's key role in the modulation of anti-inflammatory programming at the organismal level and open avenues for leveraging this knowledge in developing mitigation strategies against inflammaging.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.